1 | J-tube | - | - | - | - | 1件: 6 6 |
2 | J01GB01 | - | - | - | - | 1件: 299 299 |
3 | J05A F01 | - | - | - | - | 1件: 135 135 |
4 | J05AG04 | - | - | - | - | 1件: 18 18 |
5 | J07AH07 | - | - | - | - | 1件: 14 14 |
6 | J1081 | - | - | - | - | 1件: 56 56 |
7 | J695 | - | - | - | - | 1件: 96 96 |
8 | J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0 | - | - | - | - | 1件: 96 96 |
9 | JAK 3 | - | - | - | - | 1件: 46 46 |
10 | JAK 3 Ritlecitinib | - | - | - | - | 1件: 46 46 |
11 | JAK Inhibitor | - | - | - | - | 1件: 50 50 |
12 | JAK1 / JAK2 Inhibitor | - | - | - | - | 1件: 46 46 |
13 | JAK1 / JAK2 Inhibtor | - | - | - | - | 1件: 46 46 |
14 | Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets | 1件: Acetylcysteine Acetylcysteine | 1件: D00221
D00221
| - | - | 1件: 85 85 |
15 | Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets | 1件: Acetylcysteine Acetylcysteine | 1件: D00221
D00221
| - | - | 1件: 85 85 |
16 | Jaktinib Hydrochloride Tablets | - | - | - | - | 1件: 271 271 |
17 | Janus Kinase Inhibitor | - | - | - | - | 1件: 97 97 |
18 | Jardiance | 1件: Empagliflozin Empagliflozin | 1件: D10459
D10459
| 1件: SLC5A2 SLC5A2 💬 | - | 1件: 65 65 |
19 | JBPOS0101 | 1件: JBPOS0101 JBPOS0101 | - | - | - | 1件: 145 145 |
20 | JBT-101 | - | - | - | - | 4件: 49 49, 50, 51, 299 |
21 | JBT-101 (lenabasum) | - | - | - | - | 1件: 299 299 |
22 | Jejunal extension tube | - | - | - | - | 1件: 6 6 |
23 | Jejunal extension tube (J-tube) | - | - | - | - | 1件: 6 6 |
24 | Jevity 1.0 | - | - | - | - | 1件: 2 2 |
25 | Jevity 1.5 | - | - | - | - | 1件: 2 2 |
26 | JHL1101 | - | - | - | - | 1件: 46 46 |
27 | Jianpixiaozhong particles and Wuse Dietotherapy | - | - | - | - | 1件: 222 222 |
28 | Jin-shui Huan-xian granule | - | - | - | - | 1件: 85 85 |
29 | Jinarc | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
30 | JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG) | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
31 | JINARC - 15 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
32 | JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG) | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
33 | JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG) | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
34 | JINARC - 30 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
35 | Jinarc - Tolvaptan tablets | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
36 | Jinarc 15 mg tablets, Jinarc 45 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
37 | Jinarc 30 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
38 | Jinarc 30 mg tablets, 90 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
39 | Jinarc 30 mg tablets, Jinarc 60 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
40 | Jinarc® 15mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
41 | Jinarc® 30 Tablet | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
42 | Jing Si Herbal Tea LIQUID PACKETS | - | - | - | - | 2件: 46 46, 271 |
43 | Jintropin AQ | - | - | - | - | 1件: 78 78 |
44 | JKB-122 | - | - | - | - | 1件: 95 95 |
45 | JKB-122 in capsule or tablet form | - | - | - | - | 1件: 95 95 |
46 | JM | - | - | - | - | 2件: 6 6, 13 |
47 | JM-010 | - | - | - | - | 1件: 6 6 |
48 | JM-010 group A | - | - | - | - | 1件: 6 6 |
49 | JM-010 group B | - | - | - | - | 1件: 6 6 |
50 | JM-4 | - | - | - | - | 1件: 13 13 |
51 | JNJ 38518168 | - | - | - | - | 1件: 46 46 |
52 | JnJ 54767414 | - | - | - | - | 1件: 28 28 |
53 | JNJ-16240159-AAC | - | - | - | - | 1件: 46 46 |
54 | JNJ-31001074 | - | - | - | - | 1件: 6 6 |
55 | JNJ-38518168 | - | - | - | - | 1件: 46 46 |
56 | JNJ-38518168 (10 mg) | - | - | - | - | 1件: 46 46 |
57 | JNJ-38518168 (3 mg) | - | - | - | - | 1件: 46 46 |
58 | JNJ-38518168 (30 mg) | - | - | - | - | 1件: 46 46 |
59 | JNJ-38518168 / MTX | - | - | - | - | 1件: 46 46 |
60 | JNJ-38518168 50-mg Over Encapsulated Tablet | - | - | - | - | 1件: 46 46 |
61 | JNJ-38518168-AEK - Over Encapsulated Tablet - 50 mg | - | - | - | - | 1件: 46 46 |
62 | JNJ-38518168-ZBQ | - | - | - | - | 1件: 46 46 |
63 | JNJ-38518168-ZBQ - film-coated tablet - 10 mg | - | - | - | - | 1件: 46 46 |
64 | JNJ-38518168-ZBQ - film-coated tablet - 10mg | - | - | - | - | 1件: 46 46 |
65 | JNJ-38518168-ZBQ - film-coated tablet - 3 mg | - | - | - | - | 1件: 46 46 |
66 | JNJ-38518168-ZBQ - film-coated tablet - 30 mg | - | - | - | - | 1件: 46 46 |
67 | JNJ-38518168-ZBQ - film-coated tablet - 30mg | - | - | - | - | 1件: 46 46 |
68 | JNJ-38518168-ZBQ - film-coated tablet - 3mg | - | - | - | - | 1件: 46 46 |
69 | JNJ-39039039 | - | - | - | - | 1件: 210 210 |
70 | JNJ-39758979 | - | - | - | - | 1件: 46 46 |
71 | JNJ-39758979 (10 mg) | - | - | - | - | 1件: 46 46 |
72 | JNJ-39758979 (100 mg) | - | - | - | - | 1件: 46 46 |
73 | JNJ-39758979 (30 mg) | - | - | - | - | 1件: 46 46 |
74 | JNJ-39758979 (300 mg) | - | - | - | - | 1件: 46 46 |
75 | JNJ-39758979 / MTX | - | - | - | - | 1件: 46 46 |
76 | JNJ-39758979-AAC - enteric coated tablet - 10 mg | - | - | - | - | 1件: 46 46 |
77 | JNJ-39758979-AAC - enteric coated tablet - 100 mg | - | - | - | - | 1件: 46 46 |
78 | JNJ-39758979-AAC - enteric coated tablet - 30 mg | - | - | - | - | 1件: 46 46 |
79 | JNJ-40346527 | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 2件: 46 46, 96 |
80 | JNJ-40346527-AAC | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 96 96 |
81 | JNJ-40346527-AAC - capsule - 50 mg | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 46 46 |
82 | JNJ-42160443 | - | - | - | - | 1件: 226 226 |
83 | JNJ-54767414 | - | - | - | - | 2件: 28 28, 49 |
84 | JNJ-54781532 150 mg once daily | - | - | - | - | 1件: 97 97 |
85 | JNJ-54781532 25 mg once daily | - | - | - | - | 1件: 97 97 |
86 | JNJ-54781532 75 mg once daily | - | - | - | - | 1件: 97 97 |
87 | JNJ-54781532 75 mg twice daily | - | - | - | - | 1件: 97 97 |
88 | JNJ-54781532-AAD-10 mg | - | - | - | - | 1件: 97 97 |
89 | JNJ-54781532-AAD-30 mg | - | - | - | - | 1件: 97 97 |
90 | JNJ-54781532-AAD-5 mg | - | - | - | - | 1件: 97 97 |
91 | JNJ-55920839 | - | - | - | - | 1件: 49 49 |
92 | JNJ-56022473 | - | - | - | - | 1件: 49 49 |
93 | JNJ-64304500 | - | - | - | - | 1件: 96 96 |
94 | JNJ-64304500-AAA | - | - | - | - | 1件: 96 96 |
95 | JNJ-66525433 | - | - | - | - | 1件: 97 97 |
96 | JNJ-67484703 | - | - | - | - | 1件: 46 46 |
97 | JNJ-67864238 | - | - | - | - | 1件: 96 96 |
98 | JNJ-67896049 | - | - | - | - | 1件: 86 86 |
99 | JNJ-67896049 (ACT-293987) | - | - | - | - | 1件: 86 86 |
100 | JNJ-67896062 / ACT-064992 | - | - | - | - | 2件: 86 86, 88 |
101 | JNJ-67896062/ ACT-064992 | - | - | - | - | 2件: 86 86, 88 |
102 | JNJ-72537634 | - | - | - | - | 1件: 97 97 |
103 | JNJ-78934804 | - | - | - | - | 2件: 96 96, 97 |
104 | JNJ-80202135 | - | - | - | - | 4件: 11 11, 46, 49, 53 |
105 | JNJ31-31001074 | - | - | - | - | 1件: 6 6 |
106 | Jojoba oil | 1件: Jojoba oil Jojoba oil | - | - | - | 1件: 36 36 |
107 | Jojoba oil with broccoli sprout extract | 2件: Broccoli Broccoli, Jojoba oil | - | - | - | 1件: 36 36 |
108 | Jorveza | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
109 | Jorveza 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
110 | Jorveza 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
111 | Jorveza 1 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
112 | Jorveza 1 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
113 | JP 1730 | - | - | - | - | 1件: 6 6 |
114 | JP-1730/F01 | - | - | - | - | 2件: 6 6, 17 |
115 | JP-1730/F02 | - | - | - | - | 2件: 6 6, 17 |
116 | JP-1730/F03 | - | - | - | - | 2件: 6 6, 17 |
117 | JR-141 | - | - | - | - | 1件: 19 19 |
118 | JR-141 or Idursulfase | 1件: Idursulfase Idursulfase | 1件: D04499
D04499
| 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 |
119 | JR-171 | - | - | - | - | 1件: 19 19 |
120 | JS002 | - | - | - | - | 1件: 79 79 |
121 | JS005 | - | - | - | - | 1件: 271 271 |
122 | JSP191 | - | - | - | - | 1件: 285 285 |
123 | JTE-051 | - | - | - | - | 1件: 46 46 |
124 | JTT-251 | - | - | - | - | 1件: 86 86 |
125 | Juanbi pill | - | - | - | - | 1件: 46 46 |
126 | Juvit D3 | - | - | - | - | 1件: 6 6 |
127 | Jyseleca | 1件: Filgotinib Filgotinib | 1件: D10871
D10871
| 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
128 | Jyseleca 100 mg film-coated tablets | 1件: Filgotinib Filgotinib | 1件: D10871
D10871
| 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
129 | Jyseleca 200 mg film-coated tablets | 1件: Filgotinib Filgotinib | 1件: D10871
D10871
| 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
130 | JZP-110 | - | - | - | - | 1件: 6 6 |